Hiva Fassihi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiva Fassihi has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Alan Robert Lehmann
UK National Xeroderma Pigmentosum Service, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust London United Kingdom
4 shared publications - Paola Giunti
Ataxia Centre, Queen Square Institute of Neurology, Department of Molecular and Movement Neurosciences, University College London, United Kingdom
2 shared publications - Adam Fityan
Dermatology Department University Hospital, Southampton NHS Foundation Trust Southampton UK
1 shared publication - Adesoji Abiona
UK National Xeroderma Pigmentosum Service, Guy’s and St Thomas’ NHS Foundation Trust , London SE1 7EH , UK
1 shared publication Alain Sarasin
CNRS UMR9019 Genome Integrity and Cancers, Institut Gustave Roussy, Universite Paris-Saclay, Villejuif, France
1 shared publicationAlan Lehmann
National Xeroderma Pigmentosum Service, Department of Photodermatology, St John’s Institute of Dermatology, Guy’s and St Thomas’ Foundation Trust, London, UK
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Determinants of real-world sunscreen effectiveness: from ultraviolet radiation photobiology to human behaviour
Sunscreen is often presented as a straightforward intervention for reducing sun-induced skin damage. However, in practice its effectiveness is determined by a broad network of interacting factors rather than labelled sun protection factor (SPF) alone. Real-world protection depends not only on filter chemistry and test performance but also on wavelength coverage, formulation, durability, regulatory standards, user behaviour and public understanding. At the same time, sunscreen has become an increasingly contested topic, shaped by debates regarding systemic absorption, environmental impact, misinformation and the limitations of uniform public health messaging. This review examines the determinants of sunscreen effectiveness in the real world. Firstly, the photobiological basis of photoprotection is considered, including the differing contributions of UVB, UVA and, in selected contexts, visible light to skin damage. Secondly, the ways in which sunscreen efficacy is measured and regulated are reviewed, with particular attention to the limitations of SPF as a sole marker of protection. Thirdly, current evidence relating to human and environmental implications of sunscreen use is assessed. Finally, behavioural, social and communicative factors that influence real-world use are explored, together with emerging personalized and technological approaches to photoprotection. Overall, the evidence suggests that sunscreen effectiveness is best understood not as a fixed property of the product alone, but as the outcome of an interaction between photobiology, formulation science, regulation and human behaviour. This broader framework helps explain why scientifically efficacious products may deliver suboptimal protection in practice, and why future improvements in photoprotection will depend not only on innovation in formulations but also on clearer, more risk-stratified guidance that supports consistent use in everyday life.
- 21 September 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Open AccessDeterminants of real-world sunscreen effectiveness: from ultraviolet radiation photobiology to human behaviour
Sunscreen is often presented as a straightforward intervention for reducing sun-induced skin damage. However, in practice its effectiveness is determined by a broad network of interacting factors rather than labelled sun protection factor (SPF) alone. Real-world protection depends not only on filter chemistry and test performance but also on wavelength coverage, formulation, durability, regulatory standards, user behaviour and public understanding. At the same time, sunscreen has become an increasingly contested topic, shaped by debates regarding systemic absorption, environmental impact, misinformation and the limitations of uniform public health messaging. This review examines the determinants of sunscreen effectiveness in the real world. Firstly, the photobiological basis of photoprotection is considered, including the differing contributions of UVB, UVA and, in selected contexts, visible light to skin damage. Secondly, the ways in which sunscreen efficacy is measured and regulated are reviewed, with particular attention to the limitations of SPF as a sole marker of protection. Thirdly, current evidence relating to human and environmental implications of sunscreen use is assessed. Finally, behavioural, social and communicative factors that influence real-world use are explored, together with emerging personalized and technological approaches to photoprotection. Overall, the evidence suggests that sunscreen effectiveness is best understood not as a fixed property of the product alone, but as the outcome of an interaction between photobiology, formulation science, regulation and human behaviour. This broader framework helps explain why scientifically efficacious products may deliver suboptimal protection in practice, and why future improvements in photoprotection will depend not only on innovation in formulations but also on clearer, more risk-stratified guidance that supports consistent use in everyday life.
- Open Access
- 22 May 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2523-2528
Central Nervous System Tumors in Xeroderma Pigmentosum: Five Cases and Review of the Literature
Background: Xeroderma pigmentosum (XP) is a rare autosomal recessive DNA‐repair disorder characterized by extreme ultraviolet radiation (UVR) sensitivity, markedly increased cutaneous malignancy risk, and progressive neurological disease in approximately one‐third of patients. Emerging evidence suggests an increased risk of internal malignancies, particularly primary central nervous system (CNS) tumors. Objective: The aim of this work was to describe primary CNS tumors in patients with XP managed at the UK National XP Service and to review the literature. Methods: We retrospectively identified five genetically confirmed XP patients with primary CNS tumors followed longitudinally within the multidisciplinary UK National XP Service, including regular neurological evaluation. Results: Five patients (aged 20–79 years) developed primary CNS tumors: three XP‐C and two XP‐A. Tumors included gliomas, meningiomas, and subependymoma. CNS tumors occurred predominantly in younger patients with XP‐C, whereas late‐onset, slow‐growing meningiomas were observed in milder XP‐A phenotypes. One patient with XP‐C died of glioblastoma. Conclusions: XP is associated with primary CNS tumor risk, particularly in XP‐C and late‐onset XP‐A, supporting regular neurological assessment and targeted neuroimaging. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 22 May 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2523-2528
Open AccessCentral Nervous System Tumors in Xeroderma Pigmentosum: Five Cases and Review of the Literature
Background: Xeroderma pigmentosum (XP) is a rare autosomal recessive DNA‐repair disorder characterized by extreme ultraviolet radiation (UVR) sensitivity, markedly increased cutaneous malignancy risk, and progressive neurological disease in approximately one‐third of patients. Emerging evidence suggests an increased risk of internal malignancies, particularly primary central nervous system (CNS) tumors. Objective: The aim of this work was to describe primary CNS tumors in patients with XP managed at the UK National XP Service and to review the literature. Methods: We retrospectively identified five genetically confirmed XP patients with primary CNS tumors followed longitudinally within the multidisciplinary UK National XP Service, including regular neurological evaluation. Results: Five patients (aged 20–79 years) developed primary CNS tumors: three XP‐C and two XP‐A. Tumors included gliomas, meningiomas, and subependymoma. CNS tumors occurred predominantly in younger patients with XP‐C, whereas late‐onset, slow‐growing meningiomas were observed in milder XP‐A phenotypes. One patient with XP‐C died of glioblastoma. Conclusions: XP is associated with primary CNS tumor risk, particularly in XP‐C and late‐onset XP‐A, supporting regular neurological assessment and targeted neuroimaging. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 2 January 2026
- Published by Wiley in Clinical Genetics
- Vol. 109 (5) , 984-985
Unusual Disease‐Progression in Two Siblings With Xeroderma Pigmentosum Group G
Protein truncation mutations in the gene for XPG nuclease cause a very severe clinical phenotype. Two siblings have splicing mutations, which result in in-frame deletions and a less severe phenotype.
- 2 January 2026
- Published by Wiley in Clinical Genetics
- Vol. 109 (5) , 984-985
Open AccessUnusual Disease‐Progression in Two Siblings With Xeroderma Pigmentosum Group G
Protein truncation mutations in the gene for XPG nuclease cause a very severe clinical phenotype. Two siblings have splicing mutations, which result in in-frame deletions and a less severe phenotype.
- 22 July 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (11) , 2465-2476
Skin Cancer Induction by the Antimycotic Drug Voriconazole Is Caused by Impaired DNA Damage Detection Due to Chromatin Compaction
- 22 July 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (11) , 2465-2476
Skin Cancer Induction by the Antimycotic Drug Voriconazole Is Caused by Impaired DNA Damage Detection Due to Chromatin Compaction
- 18 April 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (9) , 1101-1103
A novel variant in PTPN11, c.1277A>G p.(His426Arg), in a patient with Noonan syndrome with multiple lentigines
Noonan syndrome with multiple lentigines (NSML) is a rare autosomal dominant condition arising from gene variants involved in the RAS-MAPK pathway. The presence of multiple skin cancers is not widely reported in NSML. We report on a novel missense variant causing NSML in a patient with an unusual distribution of lentigines and multiple skin cancers. An increased awareness of the potential for malignant change of lentigines in NSML may encourage regular skin surveillance as a mainstay of multidisciplinary management, enabling early diagnosis and management of skin cancers in this group of patients.
- 18 April 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (9) , 1101-1103
A novel variant in PTPN11, c.1277A>G p.(His426Arg), in a patient with Noonan syndrome with multiple lentigines
Noonan syndrome with multiple lentigines (NSML) is a rare autosomal dominant condition arising from gene variants involved in the RAS-MAPK pathway. The presence of multiple skin cancers is not widely reported in NSML. We report on a novel missense variant causing NSML in a patient with an unusual distribution of lentigines and multiple skin cancers. An increased awareness of the potential for malignant change of lentigines in NSML may encourage regular skin surveillance as a mainstay of multidisciplinary management, enabling early diagnosis and management of skin cancers in this group of patients.
- Open Access
- 1 December 2023
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (12) , 5044-5059
Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression
Xeroderma pigmentosum (XP) results from biallelic mutations in any of eight genes involved in DNA repair systems, thus defining eight different genotypes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and XP variant or XPV). In addition to cutaneous and ophthalmological features, some patients present with XP neurological disease. It is unknown whether the different neurological signs and their progression differ among groups. Therefore, we aim to characterize the XP neurological disease and its evolution in the heterogeneous UK XP cohort. Patients with XP were followed in the UK National XP Service, from 2009 to 2021. Age of onset for different events was recorded. Cerebellar ataxia and additional neurological signs and symptoms were rated with the Scale for the Assessment and Rating of Ataxia (SARA), the Inventory of Non-Ataxia Signs (INAS) and the Activities of Daily Living questionnaire (ADL). Patients’ mutations received scores based on their predicted effects. Data from available ancillary tests were collected. Ninety-three XP patients were recruited. Thirty-six (38.7%) reported neurological symptoms, especially in the XPA, XPD and XPG groups, with early-onset and late-onset forms, and typically appearing after cutaneous and ophthalmological symptoms. XPA, XPD and XPG patients showed higher SARA scores compared to XPC, XPE and XPV. SARA total scores significantly increased over time in XPD (0.91 points/year, 95% confidence interval: 0.61, 1.21) and XPA (0.63 points/year, 95% confidence interval: 0.38, 0.89). Hyporeflexia, hypopallesthaesia, upper motor neuron signs, chorea, dystonia, oculomotor signs and cognitive impairment were frequent findings in XPA, XPD and XPG. Cerebellar and global brain atrophy, axonal sensory and sensorimotor neuropathies, and sensorineural hearing loss were common findings in patients. Some XPC, XPE and XPV cases presented with abnormalities on examination and/or ancillary tests, suggesting underlying neurological involvement. More severe mutations were associated with a faster progression in SARA total score in XPA (0.40 points/year per 1-unit increase in severity score) and XPD (0.60 points/year per 1-unit increase), and in ADL total score in XPA (0.35 points/year per 1-unit increase). Symptomatic and asymptomatic forms of neurological disease are frequent in XP patients, and neurological symptoms can be an important cause of disability. Typically, the neurological disease will be preceded by cutaneous and ophthalmological features, and these should be actively searched in patients with idiopathic late-onset neurological syndromes. Scales assessing cerebellar function, especially walking and speech, and disability can show progression in some of the groups. Mutation severity can be used as a prognostic biomarker for stratification purposes in clinical trials.
- 1 December 2023
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (12) , 5044-5059
Open AccessNeurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression
Xeroderma pigmentosum (XP) results from biallelic mutations in any of eight genes involved in DNA repair systems, thus defining eight different genotypes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and XP variant or XPV). In addition to cutaneous and ophthalmological features, some patients present with XP neurological disease. It is unknown whether the different neurological signs and their progression differ among groups. Therefore, we aim to characterize the XP neurological disease and its evolution in the heterogeneous UK XP cohort. Patients with XP were followed in the UK National XP Service, from 2009 to 2021. Age of onset for different events was recorded. Cerebellar ataxia and additional neurological signs and symptoms were rated with the Scale for the Assessment and Rating of Ataxia (SARA), the Inventory of Non-Ataxia Signs (INAS) and the Activities of Daily Living questionnaire (ADL). Patients’ mutations received scores based on their predicted effects. Data from available ancillary tests were collected. Ninety-three XP patients were recruited. Thirty-six (38.7%) reported neurological symptoms, especially in the XPA, XPD and XPG groups, with early-onset and late-onset forms, and typically appearing after cutaneous and ophthalmological symptoms. XPA, XPD and XPG patients showed higher SARA scores compared to XPC, XPE and XPV. SARA total scores significantly increased over time in XPD (0.91 points/year, 95% confidence interval: 0.61, 1.21) and XPA (0.63 points/year, 95% confidence interval: 0.38, 0.89). Hyporeflexia, hypopallesthaesia, upper motor neuron signs, chorea, dystonia, oculomotor signs and cognitive impairment were frequent findings in XPA, XPD and XPG. Cerebellar and global brain atrophy, axonal sensory and sensorimotor neuropathies, and sensorineural hearing loss were common findings in patients. Some XPC, XPE and XPV cases presented with abnormalities on examination and/or ancillary tests, suggesting underlying neurological involvement. More severe mutations were associated with a faster progression in SARA total score in XPA (0.40 points/year per 1-unit increase in severity score) and XPD (0.60 points/year per 1-unit increase), and in ADL total score in XPA (0.35 points/year per 1-unit increase). Symptomatic and asymptomatic forms of neurological disease are frequent in XP patients, and neurological symptoms can be an important cause of disability. Typically, the neurological disease will be preceded by cutaneous and ophthalmological features, and these should be actively searched in patients with idiopathic late-onset neurological syndromes. Scales assessing cerebellar function, especially walking and speech, and disability can show progression in some of the groups. Mutation severity can be used as a prognostic biomarker for stratification purposes in clinical trials.
- Open Access
- 4 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients
Xeroderma pigmentosum (XP) is a genetic disorder caused by mutations in genes of the Nucleotide Excision Repair (NER) pathway (groups A-G) or in Translesion Synthesis DNA polymerase η (V). XP is associated with an increased skin cancer risk, reaching, for some groups, several thousand-fold compared to the general population. Here, we analyze 38 skin cancer genomes from five XP groups. We find that the activity of NER determines heterogeneity of the mutation rates across skin cancer genomes and that transcription-coupled NER extends beyond the gene boundaries reducing the intergenic mutation rate. Mutational profile in XP-V tumors and experiments with POLH knockout cell line reveal the role of polymerase η in the error-free bypass of (i) rare TpG and TpA DNA lesions, (ii) 3’ nucleotides in pyrimidine dimers, and (iii) TpT photodimers. Our study unravels the genetic basis of skin cancer risk in XP and provides insights into the mechanisms reducing UV-induced mutagenesis in the general population.
- 4 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Open AccessGenomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients
Xeroderma pigmentosum (XP) is a genetic disorder caused by mutations in genes of the Nucleotide Excision Repair (NER) pathway (groups A-G) or in Translesion Synthesis DNA polymerase η (V). XP is associated with an increased skin cancer risk, reaching, for some groups, several thousand-fold compared to the general population. Here, we analyze 38 skin cancer genomes from five XP groups. We find that the activity of NER determines heterogeneity of the mutation rates across skin cancer genomes and that transcription-coupled NER extends beyond the gene boundaries reducing the intergenic mutation rate. Mutational profile in XP-V tumors and experiments with POLH knockout cell line reveal the role of polymerase η in the error-free bypass of (i) rare TpG and TpA DNA lesions, (ii) 3’ nucleotides in pyrimidine dimers, and (iii) TpT photodimers. Our study unravels the genetic basis of skin cancer risk in XP and provides insights into the mechanisms reducing UV-induced mutagenesis in the general population.
- 1 September 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (3) , 295-308
British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022
Linked Comment: P. Wolf. Br J Dermatol 2022; 187:285–286.
- 1 September 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (3) , 295-308
British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022
Linked Comment: P. Wolf. Br J Dermatol 2022; 187:285–286.
- Open Access
- 14 January 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (1) , rjab594
Bilateral cochlear implantation in a young patient with xeroderma pigmentosum (XP-D) and progressive sensorineural hearing loss—How to do it?
Xeroderma pigmentosum (XP), a rare genetic skin condition, causes ultraviolet (UV)-induced neoplasms and possible neurological deficits including sensorineural hearingloss. We present the first case in literature of bilateral cochlear implantation (CI) in a patient with XP-D with neurodegeneration. Multi-disciplinary team members (national XP team, dermatologist, anaesthetist, theatre team, biophysicists) were involved. UV exposure from equipment and areas where the 14-year-old patient would track was measured. Maximum possible surgery was performed under operating headlights to limit higher-UV microscope exposure. Its bulb light intensity was reduced to achieve safe UV level (0–10 μW/cm2). Skin was protected under surgical drapes. Challenges included drilling unpredicted hard thick bone under low-intensity light and requiring bulkier Nucleus®-7 processor due to unanticipated increased scarring. A delayed left facial weakness was resolved with steroids. He is undergoing hearing rehabilitation. This highlights challenges of CI in XP. Its impact in preserving cognition and on neurodegeneration should also be observed.
- 14 January 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (1) , rjab594
Open AccessBilateral cochlear implantation in a young patient with xeroderma pigmentosum (XP-D) and progressive sensorineural hearing loss—How to do it?
Xeroderma pigmentosum (XP), a rare genetic skin condition, causes ultraviolet (UV)-induced neoplasms and possible neurological deficits including sensorineural hearingloss. We present the first case in literature of bilateral cochlear implantation (CI) in a patient with XP-D with neurodegeneration. Multi-disciplinary team members (national XP team, dermatologist, anaesthetist, theatre team, biophysicists) were involved. UV exposure from equipment and areas where the 14-year-old patient would track was measured. Maximum possible surgery was performed under operating headlights to limit higher-UV microscope exposure. Its bulb light intensity was reduced to achieve safe UV level (0–10 μW/cm2). Skin was protected under surgical drapes. Challenges included drilling unpredicted hard thick bone under low-intensity light and requiring bulkier Nucleus®-7 processor due to unanticipated increased scarring. A delayed left facial weakness was resolved with steroids. He is undergoing hearing rehabilitation. This highlights challenges of CI in XP. Its impact in preserving cognition and on neurodegeneration should also be observed.
- 1 January 2007
- Published by Elsevier
Contributors